Vivek Subbiah: My perspectives of tumor agnostic drug development
Vivek Subbiah recently shared on LinkedIn:
“So honored to present the “Future of Tissue-Agnostic Precision Medicine” at the triple meeting – THE NCI-EORTC-AACR meeting.
Presented my perspectives of tumor agnostic drug development. What an amazing meeting organized in Boston by American Association for Cancer Research, National Cancer Institute (NCI) and EORTC – European Organisation for Research and Treatment of Cancer
Some of my thoughts here…
- Every target is a pan target
- Tumors don’t follow rules and are malignant snowflakes.
- Every drug/every target should be explored in tumor agnostic setting
- There is no undruggable target
- Our patients cannot wait for trials to be done in every disease
Thanks to Targets23 organizers for placing this session in the Main Hall prime time.”
Source: Vivek Subbiah/LinkedIn
Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute. He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center. Dr. Subbiah’s research interests include drug development in rare cancers, immunotherapy, and radiopharmaceuticals.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023